SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 227 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.34 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $752,771 | +3.4% | 27,304 | +12.7% | 0.00% | – |
| Q2 2023 | $728,114 | -40.8% | 24,222 | -28.6% | 0.00% | -100.0% |
| Q1 2023 | $1,229,393 | +39.8% | 33,933 | +37.7% | 0.00% | 0.0% |
| Q4 2022 | $879,266 | +17.4% | 24,650 | +11.3% | 0.00% | – |
| Q3 2022 | $749,000 | -60.6% | 22,147 | -66.3% | 0.00% | -100.0% |
| Q2 2022 | $1,900,000 | -74.4% | 65,714 | -71.4% | 0.00% | -66.7% |
| Q1 2022 | $7,423,000 | -10.4% | 229,684 | -19.2% | 0.00% | -25.0% |
| Q4 2021 | $8,285,000 | +21.2% | 284,130 | +10.9% | 0.00% | +33.3% |
| Q3 2021 | $6,833,000 | -40.0% | 256,181 | -30.7% | 0.00% | -50.0% |
| Q2 2021 | $11,388,000 | +71.4% | 369,865 | +45.7% | 0.01% | +50.0% |
| Q1 2021 | $6,645,000 | +6.0% | 253,788 | +1.9% | 0.00% | 0.0% |
| Q4 2020 | $6,267,000 | +45.5% | 249,065 | +20.5% | 0.00% | +33.3% |
| Q3 2020 | $4,308,000 | -34.0% | 206,715 | -24.8% | 0.00% | -40.0% |
| Q2 2020 | $6,528,000 | +184.7% | 274,905 | +115.7% | 0.01% | +150.0% |
| Q1 2020 | $2,293,000 | -74.3% | 127,460 | -66.1% | 0.00% | -66.7% |
| Q4 2019 | $8,919,000 | -10.5% | 376,070 | +3.7% | 0.01% | -14.3% |
| Q3 2019 | $9,962,000 | -30.6% | 362,620 | -16.4% | 0.01% | -12.5% |
| Q2 2019 | $14,359,000 | -11.2% | 433,997 | -6.0% | 0.01% | -20.0% |
| Q1 2019 | $16,177,000 | -2.0% | 461,771 | -7.1% | 0.01% | -16.7% |
| Q4 2018 | $16,511,000 | -72.2% | 497,115 | -57.8% | 0.01% | -29.4% |
| Q3 2018 | $59,326,000 | -33.8% | 1,178,326 | -21.4% | 0.02% | -34.6% |
| Q2 2018 | $89,673,000 | +807.6% | 1,498,367 | +594.4% | 0.03% | +420.0% |
| Q1 2018 | $9,880,000 | +37.6% | 215,771 | +19.7% | 0.01% | 0.0% |
| Q4 2017 | $7,180,000 | -47.0% | 180,233 | -46.8% | 0.01% | -44.4% |
| Q3 2017 | $13,546,000 | +62.3% | 338,692 | +74.9% | 0.01% | +50.0% |
| Q2 2017 | $8,346,000 | +612.7% | 193,673 | +416.9% | 0.01% | +500.0% |
| Q1 2017 | $1,171,000 | +4.8% | 37,467 | -15.4% | 0.00% | 0.0% |
| Q4 2016 | $1,117,000 | -33.1% | 44,302 | -34.4% | 0.00% | 0.0% |
| Q3 2016 | $1,669,000 | +13.8% | 67,534 | -6.2% | 0.00% | 0.0% |
| Q2 2016 | $1,467,000 | +58.4% | 72,034 | +18.4% | 0.00% | 0.0% |
| Q1 2016 | $926,000 | -0.9% | 60,844 | -12.6% | 0.00% | 0.0% |
| Q4 2015 | $934,000 | -39.8% | 69,595 | -37.1% | 0.00% | 0.0% |
| Q3 2015 | $1,551,000 | -40.5% | 110,691 | -27.9% | 0.00% | -50.0% |
| Q2 2015 | $2,606,000 | +17273.3% | 153,539 | +11050.3% | 0.00% | – |
| Q1 2015 | $15,000 | -94.0% | 1,377 | -95.4% | 0.00% | – |
| Q4 2014 | $248,000 | +17.0% | 29,944 | +22.0% | 0.00% | – |
| Q3 2014 | $212,000 | +1313.3% | 24,540 | +1594.8% | 0.00% | – |
| Q2 2014 | $15,000 | -83.3% | 1,448 | -85.7% | 0.00% | – |
| Q1 2014 | $90,000 | +57.9% | 10,130 | +31.8% | 0.00% | – |
| Q4 2013 | $57,000 | -86.9% | 7,688 | -87.1% | 0.00% | – |
| Q3 2013 | $436,000 | – | 59,678 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |